美诺华：12月15日召开董事会会议

Group 1 - The core point of the article is that Meinuohua (SH 603538) announced a board meeting to discuss the repurchase and cancellation of restricted stocks, indicating ongoing corporate governance activities [1] - For the fiscal year 2024, Meinuohua's revenue composition is as follows: 96.14% from self-operated pharmaceuticals, 3.52% from trade, and 0.34% from other businesses, highlighting the company's strong focus on its core pharmaceutical operations [1] - As of the report, Meinuohua's market capitalization stands at 4.3 billion yuan, reflecting its valuation in the market [1] Group 2 - The article mentions a controversy surrounding the "Tongyan injection" product, which has annual sales of 300 million yuan, raising concerns among shareholders about the financial integrity of related parties [1] - There are allegations that several related parties have untraceable registration addresses, leading to questions about the financial management and transparency of the company [1] - The article also notes that the company Jiangsu Wuzhong is facing potential delisting, indicating significant financial distress and governance issues [1]